Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Standard BioToolsSTU:FLB -0.72%38 EBITDA Margin % is -32.61% as of Jun. 2026. GuruFocus rates STU:FLB with a GF Score™ of 38/100 and a GF Value™ of €0.60 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Standard BioTools ranks worse than 82.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Standard BioTools's EBITDA for the
three
months ended in Jun. 2026 was €-5.69 Mil. Standard BioTools's Revenue for the
three
months ended in Jun. 2026 was €17.45 Mil. Therefore, Standard BioTools's EBITDA margin for the quarter that ended in Jun. 2026 was -32.61%.
Standard BioTools (STU:FLB) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Standard BioTools EBITDA Margin % Related Terms
Standard BioTools EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Standard BioTools's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:FLB vs CV, ELMD, CATX: EBITDA Margin % Comparison
For the Medical Devices subindustry, Standard BioTools's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Standard BioTools EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Standard BioTools's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Standard BioTools (STU:FLB) has a EBITDA Margin % of -32.61% as of Jun. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Standard BioTools and its competitors. According to the industry distribution chart, Standard BioTools ranks #672 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 82.5%.
Is Standard BioTools' EBITDA Margin % too high?
Standard BioTools' current EBITDA Margin % is -32.61%. Based on the distribution chart, Standard BioTools ranks #672 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Standard BioTools has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' EBITDA Margin % compare to CV and ELMD?
According to the Medical Devices & Instruments industry distribution chart, Standard BioTools ranks #672 out of 815 companies for EBITDA Margin %. This places Standard BioTools in the lower half of its industry. The industry median EBITDA Margin % is 7.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.56, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Standard BioTools and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Standard BioTools's current EBITDA Margin % is -32.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.60, compared to a current price of €0.69 — trading 14.2% above its estimated fair value. The current EBITDA Margin % is -32.61%. Standard BioTools' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current EBITDA Margin % is -32.61% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Standard BioTools (STU:FLB) Overvalued in 2026?
Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued.
The current stock price of €0.69 is trading 14.2% above its estimated GF Value™ of €0.60.
GuruFocus considers Standard BioTools to be Modestly Overvalued.
Key valuation signals for STU:FLB:
EBITDA Margin %: -32.61%
GF Value™: €0.60 vs. price of €0.69 (14.2% above fair value)
No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
38GF Score
Get the complete analysis for STU:FLB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:FLB has been successfully added to your 
